| Fedratinib in Combination With Nivolumab (NCT05393674) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-06-14 |
| Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera (NCT06516406) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-05-06 |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (NCT04370301) | Fred Hutchinson Cancer Center | 2021-02-09 |
| Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (NCT04384692) | Fred Hutchinson Cancer Center | 2020-12-18 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (NCT04339101) | City of Hope Medical Center | 2020-11-11 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis (NCT03303950) | University of Utah | 2018-03-30 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (NCT03426969) | M.D. Anderson Cancer Center | 2018-01-31 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis (NCT03118492) | City of Hope Medical Center | 2017-05-24 |
| Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis (NCT02917096) | City of Hope Medical Center | 2016-11-13 |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis (NCT02528877) | City of Hope Medical Center | 2015-11-01 |
| P1101 in Treating Patients With Myelofibrosis (NCT02370329) | Mayo Clinic | 2015-08-12 |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis (NCT02098161) | M.D. Anderson Cancer Center | 2014-12-18 |
| JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (NCT02251821) | Fred Hutchinson Cancer Center | 2014-10-20 |
| Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (NCT01644110) | University of Ulm | 2013-08-01 |
| Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (NCT01732445) | Mayo Clinic | 2013-04-01 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (NCT01731951) | Geron Corporation | 2012-10-29 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| CC-4047 in Treating Patients With Myelofibrosis (NCT00669578) | Mayo Clinic | 2008-05-01 |
| Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis (NCT00630994) | Mayo Clinic | 2008-03-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (NCT00589563) | City of Hope Medical Center | 2007-05-01 |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases (NCT00376519) | Masonic Cancer Center, University of Minnesota | 2007-05-01 |
| Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases (NCT00438958) | The Canadian Blood and Marrow Transplant Group | 2007-03-01 |
| Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases (NCT00424242) | Northwestern University | 2007-01-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| Azacitidine in Treating Patients With Myelofibrosis (NCT00381693) | Mayo Clinic | 2006-08-01 |
| Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer (NCT00611351) | University of Nebraska | 2005-06-07 |
| Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia (NCT00445900) | Mayo Clinic | 2004-10-01 |
| Decitabine in Treating Patients With Myelofibrosis (NCT00095784) | National Cancer Institute (NCI) | 2004-09-29 |
| T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases (NCT00589602) | The Cleveland Clinic | 2004-01-01 |